Clinical Trial Update: Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing RTXM83 plus CHOP to Rituximab plus CHOP in diffuse large B-cell lymphoma has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
• RTXM83 (RTXM83)
• Rituximab (rituximab)

Snippet

Sponsor: mAbxience Research S.L. | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2019-09-26